1. 150O_PRPertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG). (13th May 2019) Authors: Huober, J; Ribi, K; Weder, P; Li, Q; Vanlemmens, L; Gerard, M-A; Lemonnier, J; Thürlimann, B; Boven, E; Bonnefoi, H Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 288PDPERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207). (23rd October 2018) Authors: Huober, J; Weder, P; Veyret, C; Thürlimann, B; Xyrafas, A; Vanlemmens, L; Guiu, S; Brain, E; Grenier, J; Dalenc, F; Levy, C; Savoye, A M; Müller, A; Membrez-Antonioli, V; Gerard, M A; Lemonnier, J; Hawle, H; Boven, E; Bonnefoi, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗